VEGF antagonists

Bibliography

• FOLKMAN J: Anti angiogenesis: new concept for therapy of solid tumours. Ann. Surg. (1972) 175:409–416.
   PubMed Web of Science ®Google Scholar
• FOLKIVIAN J: What is the evidence that tumours are angiogenesis dependent?,./ Natl. Cancer Inst. (1990) 82:4–6.
   PubMed Web of Science ®Google Scholar
• The Role of VEGF. Bicknell R, Lewis CE, Ferrara N (Eds.), Tumour Angiogenesis; Oxford Univ. Press (1997).
   Google Scholar
• DE VITA VT JR, HELLMAN S, ROSENBERG SA: Cancer, Principles and Practice of Oncology Lippincot-Raven (1997).
   Google Scholar
• SENGER DR, GALLI SJ, DVORAK AM etal.: Tumour cells secrete a vascular permeability factor that promotes accumulation of ascitic fluid. Science (1983) (219):983–985.
   Google Scholar
• OLSON TA, MOHANRAJ D, CARSON LF et al.: Vascular permeability factor gene expression in normal and neoplastic human ovaries. Cancer Res. (1994) 54:276–280.
   PubMed Web of Science ®Google Scholar
• BROWN LF, BERSE B, JACKMAN RW et al.: Expression of vascular permeability factor (VEGF) and its receptors in adenocarcinomas of the gastrointestinal tract. Cancer Res. (1993) 53:4727–4735.
   PubMed Web of Science ®Google Scholar
• FERRARA N, WINER J, BURTON T et al.: Expression of vascular endothelial growth factor does not promote transformation but confers a growth advantage in vivo to chinese hamster ovary cells. J. Clin. Invest. (1993) 91:160–170.
   PubMed Web of Science ®Google Scholar
• OLOFFSON B, PAJUSOLA K, VON EULER G etal.: Genomic organisation of the mouse and human genes for vascular endothelial growth factor B(VEGF-B) and characterisation of a second splice isoform. Bia. Chem. (1996) 271:19310–19317.
   Google Scholar
• JOUKOV V, PAJUSOLA K, KAIPANEN A etal.: A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt-4(VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J. (1996) 15:1751.
   Google Scholar
• YAMADA Y, NEZU J, SHIMANE M et al.: Molecular cloning of a novel vascular endothelial growth factor, VEGF-D. Cenomics (1997) 42:483–488.
   Google Scholar
• OGAWA S, OKU A, SAWANO A et al.: A novel type of vascular endothelial growth factor, VEGF-E (NZ-7 VEGF), preferentially utilises KDR/Flk-1 receptor and carries a potent mitotic activity without heparin binding domain. j. Biol. Chem. (1998) 273:31273–31282.
   PubMed Web of Science ®Google Scholar
• MAGLIONE D, GUERRIERO V, VIGLIETTO G et al.: Isolation of a human placenta cDNA coding for a protein related to the vascular permeability factor. Proc. Natl. Acad. Li. USA (1991) 88:9267–9271.
   PubMed Web of Science ®Google Scholar
• KIM KJ, LI B, FERRARA N et al.: The vascular endothelial growth factor proteins: identification of biologically relevant regions by neutralising monoclonal antibodies. Growth Factors (1992) 7:53–64.
   PubMedGoogle Scholar
• ROECKL W, HECHT D, SZTAJER H et al.: Differential binding, characterisation and cellular inhibition by soluble VEGF receptors 1 and 2. Experimental Cell Res. (1998) 241:161–170.
   PubMed Web of Science ®Google Scholar
• TERMAN BI, KHANDNE L, DOUGHER VEIMAZEN M etal.: VEGF receptor subtypes KDR and Flt-1 show different sensitivities to heparin and placenta growth factor. Growth Factors (1994) 11:187–195.
   Google Scholar
• ZHANG HT, SCOTT PA, MORBIDELLI L et al.: The 121 amino acid isoform of vascular endothelial growth factor is more strongly tumourigenic than other splice variants. Br J. Cancer (2000) 83:63–68.
   PubMed Web of Science ®Google Scholar
• •Demonstrated greater biological activity for VEGF121 as compared to other VEGF isoforms.
   Google Scholar
• SHIMA DT, ADAMS AP FERRARA N et al.: Hypoxic induction of vascular endothelial growth factor in retinal cells: identification and characterisation of vascular endothelial growth factor (VEGF) as the sole mitogen. Mol. Med. (1995) 1:182–193.
   Google Scholar
• SHWEIKI D, ITIN A, SOFFER D, KESHET E: Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature (1992) 359:843–845.
   PubMed Web of Science ®Google Scholar
• ••Showed that VEGF-mediated angiogenesisis induced by hypoxia.
   Google Scholar
• BANAI S, SHWEIKI D, PINSON A et al. Upregulation of vascular endothelial growth factor expression induced by myocardial ischaemia: implications for coronary angiogenesis. Cardiovasc. Res. (1994) 28:1176–1179.
   PubMed Web of Science ®Google Scholar
• ILIOPOULOS 0, LEVY AP JIANG C et al.: Negative regulation of hypoxia-inducible genes by the von Hippel Lindau protein. Proc. Natl. Acad. Sci. USA (1996) 93:10595–10599.
   Google Scholar
• BLANCHER C, HARRIS AL: The molecular basis for the hypoxia response pathway: tumour hypoxia as a therapy target. Cancer Metastases Rev (1998) 17:187–194.
   PubMed Web of Science ®Google Scholar
• MAXWELL PH, DACHS GU, GLEADLE JM et al.: Hypoxia inducible factor-1 modulates gene expression in solid tumours and influences both angiogenesis and tumour growth. Proc. Nati Acad. Sci. USA (1997) 94:8104–8109.
   PubMed Web of Science ®Google Scholar
• WEISENER MS, TURLEY H, ALLEN WE et al.: Induction of endothelial PAS domain protein-1 by hypoxia: characterisation and comparison with hypoxia-inducible factor-1 alpha. Blood (1998) 92:2260–2268.
   PubMed Web of Science ®Google Scholar
• GASPARINI G: Prognostic value of vascular endothelial growth factor in breast cancer. Oncologist 2000 5(Suppl.):37–44.
   Google Scholar
• SHIBUYA M, YAMAGUCHI S, IKEDA T etal.: Nucleotide sequence and expression of a novel human receptor- type tyrosine kinase WO closely related to the fms family. Oricogerie (1990) 5:519–524.
   Google Scholar
• TERMAN BI, CARRION ME, KOVACS E et al.: Identification of a new endothelial cell growth factor receptor tyrosine kinase. Oncogene (1991) 6:1677–1683.
   PubMed Web of Science ®Google Scholar
• LARRIVEE B, KARSAN A: Signalling pathways induced by vascular endothelial growth factor (rev). Intl Mol. Med. (2000) 5(5):447–456.
   PubMed Web of Science ®Google Scholar
• HUBBARD SR: Structural analysis of receptor tyrosine kinases. Prog. Biophys. Mol. Biol. (1999) 71:343–358.
   PubMed Web of Science ®Google Scholar
• GERBER HP, MCMURTREY A, KOWALSKI J et al.: Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidyl inositol 3' kinase/Akt signal transduction pathway. Requirement for flk-likdr activation. _J. Biol. Chem. (1998) 273:30336–30343.
   PubMed Web of Science ®Google Scholar
• MILLAUER B, PLATE KH, SHAWVER LK etal.: Glioblastoma growth inhibited in vivo by dominant negative flk-1 mutant. Nature (1994) 367:576–579.
   Google Scholar
• BERNATCHEZ PN, SOKER S, SIROIS MG: Vascular endothelial growth factor effect on endothelial cell proliferation, migration and platelet activating factor synthesis is flk-1 dependent. I Biol. Chem. (1999) 274:31047–31054.
   Web of Science ®Google Scholar
• SOKER S, TAKASHIMA S, MIAO HQ et al.: Neuropilin-1 is expressed by endothelial cell and tumour cells as an isoform specific receptor for vascular endothelial growth factor. Cell (1998) 92:735–745.
   PubMed Web of Science ®Google Scholar
• SENGER DR, LEDBETTER SR, DETMAR M et al.: Stimulation of endothelial cell migration by VPFNEGF through cooperative mechanisms involving the avI33 integrin, osteopontin and thrombin. Am. J. Pathol. (1996) 149:293–305.
   PubMed Web of Science ®Google Scholar
• SENGER DR, CONOLLY DT, VAN DE WATER L et al.: Purification and NH2 terminal amino acid sequence of guinea pig tumour secreted vascular permeability factor. Cancer Res. (1990) 50:1774–1778.
   Google Scholar
• STACKER SA, VITALI A, CAESAR C et al.: A mutant form of vascular endothelial growth factor(VEGF) that lacks VEGFR-2 activation retains the ability to induce vascular permeability. J. Biol. Chem. (1999) 49:34884–34892.
   Google Scholar
• KIM KJ, LI B, WINER J et al.: Inhibition of vascular endothelial growth factor induced angiogenesis suppresses tumour growth in vivo. Nature (1993) 362:841–844.
   PubMed Web of Science ®Google Scholar
• TANIGAWA N, AMAYA H, MATSUMARA M et al.: Correlation between expression of vascular endothelial growth factor and tumour vascularity, and patient outcome in human gastric carcinoma. J. Clin. Oncol. (1997) 15:826–832.
   PubMed Web of Science ®Google Scholar
• LINDERHOLM B, TAVELIN B, GRANKVIST K et al.: Vascular endothelial growth factor protein - a predictor of survival in primary breast cancer. Proc. of ASCO (1998) Absract 386.
   Google Scholar
• 0' BYRNE KJ, KOUKOURAKIS MI, GIATROMANOLAKI A et al.: Vascular endothelial growth factor, platelet derived growth factor and angiogenesis in non small cell lung cancer. Br. I Cancer (2000) 82(8):1427–1432.
   Google Scholar
• MATTERN J, KOOMAGI R, VOLM M: Association of vascular endothelial growth factor expression with intra tumoural microvessel density and tumour cell proliferation in human epidermoid lung carcinoma. Br j. Cancer (1996) 73:931–934.
   PubMed Web of Science ®Google Scholar
• YUAN A, CHONG-JEN YU, SOW HSONG KUO et al.: Vascular endothelial growth factor 189 mRNA isoform expression specifically correlates with tumour angiogenesis, patient survival and post operative relapse in patients with non small cell lung cancer. I Clin. Oncol. (2001) 19:432–441.
   Google Scholar
• TAKAHASHI Y, KITADAI Y, BUCANA CD et al.: Expression of vascular endothelial growth factor and its receptor KDR correlates with vascularity, metastases and proliferation of human colon cancer. Cancer Res. (1995) 55:3964–3968.
   PubMed Web of Science ®Google Scholar
• WEIDNER N, CARROLL PR, FLAX J et al.: Tumour angiogenesis correlates with metastases in invasive prostate carcinoma. Am. j. Pathol. (1993) 143:401–409.
   PubMed Web of Science ®Google Scholar
• •Confirmed that microvascular density correlates with metastases in invasive prostatic carcinoma, confirming similar observations in breast and lung cancers.
   Google Scholar
• WU H, MCLEOD AR, LIMA WF et al.: Identification and partial purification of human dsRNAse activity. A novel terminating mechanism for oligoribonucleotide antisense drugs. j Biol. Chem. (1998) 273:2532–2542.
   Google Scholar
• MCMAHON G: Vascular endothelial growth factor signalling in tumour angiogenesis. Oncologist (2000) 5\(Supp1.1):3–10.
   Google Scholar
• SALEH M, STACKER SA, WILKS AF: Inhibition of growth of C6 glioma cells PI vivo by expression of antisense vascular endothelial growth factor sequence. Cancer Res. (1996) 56:393–401.
   PubMed Web of Science ®Google Scholar
• NGUYEN JT, WU E HLATKY L et al.: Adeno associated virus mediated delivery of anti-angiogenic factors as an anti tumour strategy. Cancer Res. (1998) 58:5673–5677.
   Google Scholar
• CLAFFEY KE BROWN LE DEL AGUILA LF et al.: Expression of vascular permeability factor/vascular endothelial factor by melanoma cells increases tumour growth, angiogenesis and experimental metastases. Cancer Res. (1996) 56:172–181.
   PubMed Web of Science ®Google Scholar
• •Showed correlation between VEGF expression and experimental tumour angiogenesis and metastases in an in vitro model.
   Google Scholar
• CHENG SY, HUANG HJ, NAGANE Met al.: Suppression of glioblastoma angiogenicity and tumourigenicity by inhibition of endogenous suppression of vascular endothelial growth factor. Proc. Natl. Acad. Li. USA (1996) 93:8502–8507.
   Google Scholar
• WOLFF JA, MALONE RW, WILLIAM P et al.: Direct gene transfer into mouse muscle in vivo. Science (1990) 247:1465–1468.
   PubMed Web of Science ®Google Scholar
• NGUYEN JT: VEGF as a target for cancer gene therapy. Cancer gene therapy 2000: past achievements and future challenges. H Kluwer (Ed.), Acad./Plenum publishers.
   Google Scholar
• PARRY TJ, CUSHMAN C, GALLEGOS AM et al.: Bioactivity of anti-angiogenic ribozymes targeting Flt-1 and KDR mRNA. Nucleic acid Res. (1999) 27:2569–2577.
   PubMed Web of Science ®Google Scholar
• PARKER VP, SANDBERG JA, SMITH Jet al.: Phase I and pharmacokinetic studies of Angiozyme, a synthetic ribozyme targeting the VEGF receptor Flt-1. Proc. ASCO (2000) Abstract 703.
   Google Scholar
• WENG DE, WEISS P, GANAPATHI R et al.: A Phase I/II study of repetitive dose Angiozyme, a ribozyme targeting the Flt-1 receptor for VEGF. Proc. Eleventh NCI-EORTC-AACR symposium (2000) Abstract 267.
   Google Scholar
• YOKITA A, ASANO M, OKAMOTO T et al.: Suppression of ascites formation and reaccumulation associated with human ovarian cancer by anti-VPF monoclonal antibody in vivo. Anti-Cancer Res. (2000) 20(1A):155–160.
   Google Scholar
• PRESTA LG, CHEN H, O'CONNOR SJ et al.: Humanisation of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumours and other disorders. Cancer Res. (1997) 57:4593–4599.
   Google Scholar
• GORDON MS, MARGOLIN K, TALPAZ M et al.: Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor antibody in patients with advanced cancer. j. Oncol. (2001) 19:843–850.
   Google Scholar
• ••Demonstrated biological activity ofrhumAb VEGF in humans.
   Google Scholar
• REESE D, FROHLICH M, BOK R et al.: A Phase II trial of humanised monoclonal anti-vascular endothelial growth factor antibody (RhuMAb VEGF) in hormone refractory prostate cancer (HRPC). Proc. ASCO (1999) Abstract 1355.
   Google Scholar
• SLEDGE G, MILLER K, NOVOTNY W etal.: A Phase II trial of single agent rhuMAb VEGF (recombinant humanised monoclonal antibody to vascular endothelial cell growth factor) in patients with relapsed metastatic breast cancer. Proc. ASCO (2000) Abstract 5C.
   Google Scholar
• DEVORE RF, FEHRENBACHER L, HERBST SR et al.: A randomised Phase II trial comparing RhuMAb VEGF plus Carboplatin/Paclitaxel(CP) to CP alone in patients with stage III/IV non small cell lung cancer. Proc. ASCO (2000) Abstract 1896.
   Google Scholar
• BERGSLAND E, HURWITZ H, FEHRENBACHER L et al.: A randomised Phase II trial comparing RhuMAb VEGF plus 5-fluorouracil/leucovorin(FU/LV) to FU/LV alone in patients with metastatic colorectal cancer. Proc. ASCO (2000) Abstract 939.
   Google Scholar
• ASANO M, YUKITA A, MATSUMOTO T et al.: An anti human VEGF monoclonal antibody MV833 that exhibits potent anti tumour activity PI vivo. Hybridoma (1998) 17(2):185–190.
   PubMed Web of Science ®Google Scholar
• BURGER AM, HENDRIKS HR, TANG T et al.: Enhanced anti tumour activity of anti-VEGF antibody HuMV833 given in combination with gemcitabine in human pancreatic tumour xenografts. Proc. Eleventh NCIEORTC-AACR symposium (2000) Abstract 579.
   Google Scholar
• JAYSON GC, MULATERO C, RANSON M et al.: Anti-VEGF antibody HuMv833: An EORTC biological treatment development. Phase I toxicity, pharmacokinetic and pharmacodynamic trial. Proc. Eleventh NCIEORTC-AACR symposium. Abstract 270.
   Google Scholar
• SKOBE M, ROCKWELL P, GOLDSTEIN N et al.: Halting angiogenesis suppresses carcinoma cell invasion. Nat. Med. (1997) 3:1222–1227.
   PubMed Web of Science ®Google Scholar
• PREWETT M, HUBER J, LI Y et al.: Antivascular endothelial growth factor receptor(flk-1) monoclonal antibody inhibits tumour angiogenesis and growth of several mouse and human tumours. Cancer Res. (1999) 59:5209–5218.
   PubMed Web of Science ®Google Scholar
• INOUE K, SLATON JW, DAVIS DW et al.: Treatment of human metastatic transitional cell carcinoma of the bladder in a murine model of the anti vascular endothelial growth factor receptor monoclonal antibody DC101 and Paclitaxel. Chia. Cancer Res. (2000) 6(7):2635–2643.
   PubMed Web of Science ®Google Scholar
• XIAOQIANG K, JACK SHI, PATEL D et al.: Enhanced suppression of melanoma tumour growth and metastasis by combined therapy with anti-VEGF receptor and anti gp 75 monoclonal antibody. Proc. Eleventh NCIEORTC-AACR symposium. Abstract 499.
   Google Scholar
• ZHENPING ZHU, WITTE L, HICKLIN DJ et al.: Safety profile in primates and anti-angiogenic activity in murine and canine models of a chimeric antibody against the vascular endothelial growth factor receptor-2. Proc. ASCO (2000) Abstract 1793.
   Google Scholar
• LIN P, SANKAR S, SHAN S et al.: Inhibition of tumour growth by targeting tumour endothelium using a soluble vascular endothelial growth factor receptor. Cell Growth Differ. (1998) 9:49–58.
   PubMedGoogle Scholar
• GOLDMAN CK, KENDALL RL, CABRERA G et al.: Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumour growth, metastases and mortality rate. Proc. Natl. Acad. Sci. USA (1998) 95:8795–8800.
   PubMed Web of Science ®Google Scholar
• HOLMGREN L. O&REILLY MS, FOLKMAN J: Dormancy of micro metastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nature Med. (1995) 1:149–153.
   Google Scholar
• GERBER HP, RYAN AM, FERRARA N et al.: Vascular endothelial growth factor couples hypertrophic cartilage remodelling, ossification and angiogenesis during endochondral bone formation. Nature Med. (1999) 5:623–628.
   PubMed Web of Science ®Google Scholar
• SOKER S, SCHUCH G, MACHLUF Met al.: Novel delivery system of a VEGF antagonist using encapsulated cells for tumour therapy. Proc. ASCO (2000) Abstract 1877.
   Google Scholar
• MENDEL DB, LAIRD AD, SMOLICH BD et al.: Development of 5U5416, a selective small molecule inhibitor of VEGF receptor tyrosine kinase activity as an anti-angiogenic agent. Anticancer Drug Design (2000) 15:29–41.
   PubMedGoogle Scholar
• FONG TA, SHAWVER LK, SUN L et al.: SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor(flkiltdr) that inhibits tyrosine kinase catalysis, tumour vascularisation and growth of multiple tumour types. Cancer Res. (1999) 59:99–106.
   PubMed Web of Science ®Google Scholar
• •Demonstrated activity of SU-5416 - an RTK inhibitor in in vivo models.
   Google Scholar
• ARMESILLA AL, LORENZO E, GOMEZDEL ARCO P et al. Vascular endothelial growth factor activates nuclear factor of activated T cells in human endothelial cells: a role for tissue factor gene expression. Mol.
   Google Scholar
• CHERRINGTON JM, LAIRD AD, inhibitor, in tumour xenograft models. Clin.
   Google Scholar
• VAJKOCZY P, MENGER MD, VOLLMAR B et al.: Inhibition of tumour growth, angiogenesis and microcirculation by the novel Flk-1 inhibitor SU5416 as assessed by intravital multifluorescence
   Google Scholar
• SHAHEEN RM, DAVIS DW, LIU W et al.: Anti-angiogenic therapy targeting the tyrosine kinase receptor for vascular endothelial growth factor receptor inhibits the growth of colon cancer liver metastases 5416.
   Google Scholar
• ROSEN L, MULAY M, MAYERS A et al.: Phase I dose escalating trial of SU5416, a Abstract 618.
   Google Scholar
• CROPP GF, HANNAH AL: 5U5416 a molecularly targeted novel anti-angiogenesis
   Google Scholar
• GIACC ONE G, ROSEN L, KUENEN B etal.: Dose finding study of Cisplatin,
   Google Scholar
• MILES S, ARASTEH K, GILL P et al.: A multi-centre dose escalating study of 5U5416 in AIDS-related kaposfs sarcoma. Proc. ASCO (2000) Abstract 683.
   Google Scholar
• ROSEN PJ, AMADO R, HECHT JR et al.: A Phase I/II study of SU5416 in
   Google Scholar
• SHAWVER LK, STRAWN LM, FONG TA et al.: U6668 is a potent broad spectrum angiogenesis inhibitor that exhibits anti-tumour properties. Proc. Am. Assoc. Cancer Res. (1999) 40:723a.
   Google Scholar
• LAIRD AD, VAJKOCZY P, SHAWVER LK et al.: 5U6668 is a potent anti-angiogenesis and anti-tumour agent that induces regression of established tumours. Cancer Res. (2000) 60(15):4152–60. Established in vivo efficacy of oral RTK inhibitors.
   Google Scholar
• MEETING REPORT: Biological basis of anti-angiogenic therapy. Acta Histochemica (2000) 102:117–127.
   PubMedGoogle Scholar
• ROSEN L, HANNAH A, ROSEN P et al.: Phase I dose escalating trial of oral 5U6668, a novel multiple receptor tyrosine kinase inhibitor in patients with advanced malignancies. Proc. Eleventh NCTEORTC-AACR symposium Abstract 581.
   Google Scholar
• ROSEN L, HANNAH A, ROSEN P et al.: Phase I dose escalating trial of oral 5U6668, a novel multiple receptor tyrosine kinase inhibitor in patients with selected advanced malignancies. Proc. ASCO (2000) Abstract 708.
   Google Scholar
• SMOLICH BD, YUEN HA, WEST KA et al.: 5U5416 and 5U6668 inhibit biological function of c-kit in a myeloid leukaemia cell line and in AML blasts. Proc. Eleventh NCI-EORTC-AACR symposium. Abstract 265.
   Google Scholar
• HENNEQUIN LF, THOMAS AP, JOHNSTONE C et al.: The design and synthesis of a novel orally active VEGF receptor tyrosine kinase inhibitor. Proc. Am. Assoc. Cancer Res. (1999) 40:4159.
   Google Scholar
• WEDGE SR, OGILVIE DJ„ DUKES Met al.: ZD4190: an orally active inhibitor of vascular endothelial growth factor signalling with broad spectrum anti tumour efficacy. Cancer Res. (1999) 60:970–975.
   Google Scholar
• WEDGE SR, OGILVIE DJ, DUKES M et al.: Chronic and acute effects of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor on established human tumour xenografts. Proc. Eleventh NCIEORTC-AACR Symposium. Abstract 268.
   Google Scholar
• WOOD JM:. BOLD G, BUCHDUNGER E et al.: PTK787/ZK222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinase, impairs vascular endothelial growth factor induced responses and tumour growth after oral administration. Cancer Res. (2000) 15:2178–2189.
   Google Scholar
• •Established in vivo efficacy of oral RTK inhibitors.
   Google Scholar
• DREVS J, HOFMANN I, HUGENSCHMIDT H et al.: Effects of PTK787/ZK222584, a specific inhibitor of VEGF receptor tyrosine kinase on primary tumours, metastases, vessel density and blood flow in a murine renal cell carcinoma model. Cancer Res. (2000) 60(17):4819–4824.
   PubMed Web of Science ®Google Scholar
• XU L, YONEDA J, HERRERA C etal.: Inhibition of malignant ascites and growth of human ovarian carcinoma by oral administration of a potent inhibitor of the vascular endothelial growth factor receptor tyrosine kinases. Int. j Oncol. (2000) 16:445–454.
   Google Scholar
• DREVS J, MROSS K, REUSCH P et al.: Phase I dose escalation pharmacokinetic study of a novel vascular endothelial growth factor receptor (VEGF) inhibitor, PTK787/ ZK222584 (PTK/ZK). Eur. J. Cancer (1999) 35\(Suppl. 4):283. Abstract 1137.
   Google Scholar
• FABBRO D, BUCHDUNGER E, WOOD J et al.: Inhibitors of protein kinases: CGP41251, a protein kinase inhibitor with potential as an anti-cancer agent. Pharmacol. Ther. (1999) 82:293–301.
   PubMed Web of Science ®Google Scholar
• BEGEMANN M, KASHIMAWO SA, HEITJAN DF et al.: Treatment of human glioblastoma cells with the staurosporine derivative CGP41251 inhibits CDC2 and CDK2 kinase activity and increases radiation sensitivity. AntiCancer Res. (1998) 18(4A):2275–2282.
   Google Scholar
• VAN GUN R, VAN TELLINGEN 0, HAVERKATE E et al.: Pharmacokinetics and metabolism of the staurosporine analogue CGP41251 in mice. Invest. New Drugs (1999) 17:29–41.
   Google Scholar
• THAVASU E PROPPER D, MCDONALD A et al.: The protein kinase C inhibitor CGP41251 suppresses cytokine release and extracellular signal regulated kinase 2 expression in cancer patients. Cancer Res. (1999) 59(16):3980–3984.
   PubMed Web of Science ®Google Scholar
• LUO JC, YAMAGUCHI S, SHINKAI A et al.: Significant expression of vascular endothelial growth factor/vascular permeability factor in mouse ascites tumours. Cancer Res. (1998) 58:2652–2660.
   PubMed Web of Science ®Google Scholar
• YANO S, SHINOHARA H, KUNIYASU H et al.: Formation of pleural effusion by human lung adenocacinoma directly correlates with expression of VEGFNPE Proc. Am. Assoc. Cancer Res. (1999) 40:2279.
   Google Scholar
• ZEBROWSKI BK, LIU W, RAMIREZ K et al.: Markedly elevated levels of vascular endothelial growth factor in malignant ascites. Ann. Surg. Oricol. (1999) 6:373–378.
   PubMed Web of Science ®Google Scholar
• THICKETT DR, ARMSTRONG L, MILLAR AB et al.: Vascular endothelial growth factor in inflammatory and malignant pleural effusions. Thorax (1999) 54:707–710.
   PubMed Web of Science ®Google Scholar
• VERHUEL HM, HOEKMAN K, JORNA AS etal.: Targeting vascular endothelial growth factor blockade: Ascites and pleural effusion formation. Oncologist (2000) 5\(Suppl. 1):45–50.
   Google Scholar
• YANO S, HERBST RS, SHINOHARA H et al.:. Treatment for malignant pleural effusion of human lung adenocarcinoma by inhibition of vascular endothelial growth factor receptor tyrosine kinase phosphorylation. Clin. Cancer Res. (2000) 6(3):957–965.
   Google Scholar
• AIELLO LP, WONG JS: Role of vascular endothelial growth factor in diabetic vascular complications. Kidney Int. (2000) 21\(Suppl. 77):113–119.
   Google Scholar
• AIELLO LP, PIERCE EA, FOLEY ED et al.: Suppression of retinal neovascularisation in vivo by inhibition of vascular endothelial growth factor using soluble VEGF- receptor chimeric protein. Proc. Nati Acad. Sci. USA (1995) 92:10457–10461.
   PubMed Web of Science ®Google Scholar
• ROBINSON GS, PIERCE EA, ROOK SL et al.: Oligo deoxyribonucleotides inhibit retinal neovascularisation in a murine model of proliferative retinopathy. Proc. Natl. Acad. Sci. USA (1996) 93:4851–4856.
   PubMed Web of Science ®Google Scholar
• MIOTLA J, MACIEWICZ R, KENDREW J et al.: Treatment with soluble vascular endothelial growth factor receptor reduces disease severity in murine collagen induced arthritis. Lab. Invest. (2000) 80(8):1195–1205.
   PubMed Web of Science ®Google Scholar
• SMYTH AP, ROOK SL, DETMAR M et al.: Antisense oligonucleotides inhibit vascular endothelial growth factor/vascular permeability factor expression in normal human epidermal keratinocytes. I Invest. Dermatol. (1997) 108(4):523–526.
   PubMed Web of Science ®Google Scholar
• KAMAT BR, BROWN LE SENGER DR et al.: Expression of vascular permeability factor/vascular endothelial growth factor by human granulosa and theca lutein cell. Role in corpus luteum development. Am. Pathol. (1995) 146(1):157–165.
   Google Scholar
• BRASCH R, TURETSCHEK K: MRI characterisation of tumours and grading angiogenesis using macro molecular contrast media: status report. Eur. j Radiol. (2000) 34(3):148–155.
   PubMedGoogle Scholar
• •Describes utility of MMCM as a non-invasive technique for assessment of activity of anti-VEGF agents.
   Google Scholar
• TOFTS PS, KERMODE AG: Measurement of the blood brain barrier permeability and space using dynamic MRI imaging. I. Fundamental concepts. Magn. Resat]. Med. (1991) 17(2):357–367.
   Google Scholar
• 0' DONNELL A, TRIGO JM, BANERJI U et al.: A Phase I trial of the vascular endothelial growth factor inhibitor SU5416 incorporating dynamic contrast MRI assessment of vascular permeability. Proc. ASCO (2000) Abstract 685.
   Google Scholar
• MULLANI N, HERBST R, ABBRUZZESE J et al.: Anti angiogenic treatment with endostatin results in uncoupling of blood flow and glucose metabolism in human tumours. Clin. Positron imaging (2000) 3(4):151.
   PubMedGoogle Scholar
• WALLHAUS TR, LACY J, WHANG J et al.: Human biodistribution and dosimetry of the PET perfusion copper-62-PTSM. Nucl. Med. (1998) 39(11):1958–1964.
   Web of Science ®Google Scholar
• BYRNE GJ, GHELLAL A, BUNDRED NJ eta].: Serum soluble vascular cell adhesion molecule-1: role as surrogate marker for angiogenesis. I Natl. Cancer Inst. (2000) 92(16):1329–1336.
   Google Scholar
• •Evaluates role of VCAM-1 as a surrogate marker for angiogenesis.
   Google Scholar
• TEICHER BA, SOTOMAYOR EA, HUANG ZD: Anti-angiogenic agents potentiate cytotoxic cancer therapies against primary and metastatic disease. Cancer Res. (1992) 52:6702–6704.
   PubMed Web of Science ®Google Scholar
• •Demonstrated synergistic activity of anti-angiogenic agents with cytotoxic chemotherapy in in vivo models.
   Google Scholar
• TEICHER BA, HOLDEN SA, ARA G et al.: Potentiation of cytotoxic cancer therapies by TNP-470 alone and with other anti-angiogenic agents. Int. J. Cancer (1994) 57:920–925.
   PubMed Web of Science ®Google Scholar
• SCHLINGEMANN RO, VAN HINSBERGH VWM: Role of VPFNEGF in eye disease. Br j. Ophthalmol. (1997) 81:501–512.
   PubMed Web of Science ®Google Scholar
• SUN L, TRAN N, TANG F et al.: Synthesis and biological evaluations of 3-substituted Indolin-2-ones: A novel class of tyrosine kinase inhibitors that exhibit selectivity towards particular receptor tyrosine kinases. I Med. Chem. (1998) 41:2588–2603.
   PubMed Web of Science ®Google Scholar
• SUN L, TRAN N, LIANG C et al.: Identification of substituted 34(4,5,6,7-tetrahydro-1H-indo1-2-yl)methylenel-1,3-dihydroindo1-2-ones as growth factor receptor inhibitors for VEGF-R2(Flk-1/ KDR), FGF-R1, and PDGF-R13 tyrosine kinases. j Med. Chem. (2000) 43:2655–2663.
   PubMed Web of Science ®Google Scholar
• HENNEQUIN LF, THOMAS AP JOHNSTONE C et al.: Design and structure-activity relationship of a new class of potent VEGF receptor tyrosine kinase inhibitors. j. Med. Chem. (1999) 42:5369–5389.
   Google Scholar
• BOLD G, ALTMANN KH, FREI J et al.: New anilinophthalazines as potent and orally well absorbed inhibitors of the VEGF receptor tyrosine kinases useful as antagonists of tumour-driven angiogenesis. j. Med. Chem. (2000) 43:2310–2323.
   PubMed Web of Science ®Google Scholar